Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.